Kaneka officially starts continuous manufacturing under GMP

Food and Healthcare Press Releases Tuesday August 14, 2018 15:18
TOKYO--14 Aug--PRNewswire/InfoQuest
Commercial production utilizing flow chemistry began June 2018 at Kaneka Singapore

Kaneka Corporation (Headquarters: Minato-ku, Tokyo; President: Mamoru Kadokura) have installed continuous manufacturing equipment to be applied to pharmaceutical products at Kaneka Singapore Co. (Pte.) Ltd, (Headquarters: Singapore; President: Kazuhiko Yamada) with commercial production under cGMP already underway as of June 2018.

In the field of small molecule pharmaceutical products, the recent demands have begun to   trend toward an increased number of more diversified and smaller volume targets. With these changes, more efficient production technology is needed to address the broad range of targets now required. Continuous manufacturing, or Flow Chemistry, is a manufacturing technology that allows the introduction   of raw materials with little to no operator exposure and presents an   easy, safe and convenient approach to manufacturing, including reactions that may require tough or dangerous conditions under typical batch reaction conditions. Our equipment is a unique, Kaneka designed reactor that allows diversity of application through the ability to select the relevant parameters of the reaction tubing based on laboratory and scale-up research providing the highest performance of reactions. Kaneka Singapore has been qualified as a manufacturer from the US FDA *1 in 2017, and we expect to apply this   continuous manufacturing infrastructure to various Regulatory Starting Material (RSM), Intermediate, and API projects, including targets requiring GMP *2 production.

Kaneka has capability from process development to commercial production with excellent quality assurance, and we now aim to expand our solution services in the Health Care business field utilizing this new technology.

*1 Abbreviated name of Food and Drug Administration. It is an agency within the Department of Health and Human Services in US and   has responsibility for regulating the manufacturing, marketing, and distribution of pharmaceutical products.

*2 Abbreviated name of Good Manufacturing Practice, the recommended guidelines and minimum requirements to ensure that products are consistently high in quality.
< Kaneka Singapore Co. (Pte.) Ltd. >
Representative: CEO, Kazuhiko Yamada
Paid-in Capital: 16 million Singapore dollars
Headquarter: Singapore
Establishment: 1979
Business field: Sales and manufacturing of pharmaceutical products.
Contact:
Alan Walker
VP Pharma, Kaneka Americas Holding
(212) 705-4392
Photo - https://mma.prnewswire.com/media/729329/Kaneka_Press_Release_Image.jpg
Logo - https://mma.prnewswire.com/media/635217/Kaneka_Corporation_Logo.jpg

Latest Press Release

Venus Medtech Launches Global Advisory Board to Target for International Market

Venus Medtech (Hangzhou) Inc., a Chinese medical device company specializing in transcatheter valve replacement therapy, has retained four world-renowned experts specialized in interventional cardiovascular to form a Global Advisory Board. The Board...

Future Health Index, Commissioned by Philips, Identifies Key Recommendations for Better Health Information Exchange to Drive Value in Healthcare

Royal Philips (NYSE: PHG) (AEX: PHIA), a global leader in health technology, today released a new Future Health Index (FHI) report " Moving data to the heart of health systems: Increasing vital technology adoption to make value-based healthcare a reality...

PULSUS Group collaborates with Anbu Kochi to Contribute towards Kerala Flood Victims

In a humanitarian effort, PULSUS Group - in collaboration with Anbu Kochi - is responding to the calamity of the recent, unprecedented floods in the Indian state of Kerala by providing contributions to aid relief and rehabilitation measures. PULSUS Group...

Menarini Ricerche Announces New Positive Results in Acute Myeloid Leukemia Cell Lines for MEN1112/OBT357 at the 60th Annual SIC Meeting

Menarini Ricerche will present tomorrow, September 20th, at the 60th Annual Meeting of the Italian Cancer Society (SIC), new preclinical data showing that pre-treatment with 5-Azacytidine and Decitabine enhances the Antibody-dependent cellular...

Experts Call for Improved Identification of #High Burden# Rosacea Patients in Everyday Practice

- Additional analysis of global survey data reveals quality of life is impacted by several factors extending beyond severity of rosacea alone Additional analysis of a global survey conducted and presented earlier this year, as an expert-authored report...

Related Topics